Adstiladrin (nadofaragene firadenovec) for NMIBC — Oncology (Intravesical) - Adstiladrin UM Medical Policy
Customize your policy alerts
Sign up for all Aspirus Arise policy alerts
Know when Aspirus Arise releases new policies or updates existing guidance.
Monitor payer policy activity
Covers prior authorization, coverage criteria, dosing, and approval durations for Adstiladrin intravesical therapy in adults with high-risk BCG-unresponsive non‑muscle invasive bladder cancer; applies to Aspirus Medicare plans and requires specialist prescribing or consultation.
Policy name changed from 'Oncology (Other) - Adstiladrin UM Medical Policy' to 'Oncology (Intravesical) - Adstiladrin UM Medical Policy'.
Approval duration language modified: removed 1 year approval and changed to 'approve for the duration noted'; initial therapy approval defined as 4 months (to allow 2 doses) and continuation approvals of 3 months for ongoing therapy.
Criteria for initial therapy refined to require patient be 6gt;=18, have high-risk BCG-unresponsive disease, have CIS or high-grade Ta/T1 without CIS, and prescribing by or in consultation with a urologist or oncologist.
Added option for approval of patients currently receiving Adstiladrin for 3 months if in remission or cytology-positive with imaging/cystoscopy negative disease and prescribed by or in consultation with urology/oncology.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.